Abstracts tagged "Jak inhibitor"

Abstract Number: 1209 • ACR Convergence 2021
Plasma Calprotectin as a Biomarker of Active Synovitis in Rheumatoid Arthritis: A Clinical and Ultrasound Study in Patients Treated with Il6 and JAK Inhibitors
Beatriz Frade-Sosa¹, Andrés Ponce², Roberto Gumucio³, José inciarte-Mundo⁴, María Torradeflot⁵, Virginia Ruiz-Esquide³, Rosa Morlà², Ana Belén Azuaga⁶, Núria Sapena², Marta Bassas², Julio Ramirez³, Juan D Cañete⁶, Jose A Gomez-Puerta¹ and Raimon Sanmarti¹, ¹Hospital Clínic de Barcelona, Barcelona, Spain, ²Rheumatology Department, Hospital Clínic, Barcelona, Spain, ³Rheumatology departmen. Hospital Clinic de Barcelona, Barcelona, Spain, ⁴Institut d'Investigacions Biomèdiques August Pi i Sunyer,( IDIBAPS), Barcelona, Spain, ⁵Immunology Department, Centre de Diagnòstic Biomèdic, Hospital Clínic de Barcelona, Universitat de Barcelona, IDIBAPS, Barcelona, Spain, ⁶Rheumatology Department, Hospital Clinic, Barcelona, Spain
Background/Purpose: IL6 inhibitors (IL6i) have a dramatic effect on acute phase reactants (AFR) such as C reactive protein (CRP) in rheumatoid arthritis (RA). However, CRP…
Abstract Number: 1545 • ACR Convergence 2021
Safety of JAK Inhibitor in Patients with Rheumatoid Arthritis Who Developed Reactivation of Herpes Zoster Virus After Receiving JAK Inhibitor
Wonho Choi¹, Soo Min Ahn², Yong Gil Kim¹, Chang-Keun Lee¹, Bin Yoo² and Seokchan Hong¹, ¹Asan Medical Center, Seoul, Republic of Korea, ²ASAN MEDICAL CENTER, Seoul, South Korea
Background/Purpose: Janus kinase inhibitor (JAKi) increases the risk of the reactivation of herpes zoster (HZ) virus and may thus be temporarily discontinued in cases of…